<DOC>
	<DOCNO>NCT01581294</DOCNO>
	<brief_summary>NOR-DMARD register-based longitudinal observational study main objective study effectiveness treatment inflammatory joint disease biological disease modify anti-rheumatic drug ( DMARDs ) clinical practice , measure disease activity , health relate quality life , function joint damage , study long-term safety treatment . Other objective include assessment cost-effectiveness treatment , identify validate clinical , genetic immunological predictor efficacy adverse event , assess impact treatment biological DMARDs work participation work productivity , investigate different strategy use biological DMARDs , assess performance different outcome measure , ensure systematic timely follow-up patient treat biological DMARDs .</brief_summary>
	<brief_title>The Norwegian Antirheumatic Drug Register</brief_title>
	<detailed_description>This study modification , extension , NOR-DMARD study conduct 5 Norwegian rheumatology department period 2000-2012 . The study include structure follow-up study visit baseline ( start biological drug ) 3 , 6 , 9 , 12 month every 6 month thereafter . Each study visit include clinical assessment , patient-reported outcome measurement acute-phase reactant . The data collection also include blood sample biobank baseline 3 month , annual radiograph hand foot patient peripheral arthritis . Adverse event data systematically record , also retrieve linkage register .</detailed_description>
	<mesh_term>Joint Diseases</mesh_term>
	<criteria>Age &gt; 18 year Diagnosis rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis , spondyloarthritis , adult juvenile idiopathic arthritis , undifferentiated arthritis , inflammatory arthritis Clinical indication start new treatment biological disease modify antirheumatic drug kinase inhibitor Unwillingness unability give write informed consent Psychiatric mental disorder , alcohol abuse abuse substance , language barrier factor make adherence study protocol impossible Participation blind RCTs study incompatible NORDMARD study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Psoriatic arthritis</keyword>
	<keyword>Ankylosing spondylitis</keyword>
	<keyword>Spondyloarthritis</keyword>
</DOC>